This project aims to create a synthetic neutralizing human antibody based on a virtual model. It also proposes an antibody measurement system based on Flow Cytometry, which is far more sensitive and reliable than current serological methods. This will provide a more...
Identification and optimization of PIKfyve inhibitors that can achieve results that are directly transferable to the market.The project aims to identify effective drugs against the SARS-CoV-2 virus, which can act at the level of PIKfyve lipid kinase inhibition. A...
Treatment of symptoms associated with coronavirus-induced acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) The project aims to optimize two types of antibodies: anti-C5a and anti-C5aR1, previously developed in the laboratory. The aims are: (1)...
Rapid generation of human antibodies that neutralize SARS-CoV-2. The success of vaccines generally depends on the generation of antibodies, also known as immunoglobulins, which are proteins that circulate in the blood and that, when they recognise foreign substances...
Find new combinations of antivirals to inhibit SARS-CoV-2.When a vaccine is not yet available, antivirals (which are a type of drug used for the treatment of infections produced by viruses) are the most effective resource for inhibiting replication, that is,...
Identify drugs in commercial use or in ongoing clinical development that can immediately initiate a phase II/III clinical trial for COVID-19.Effective SARS-CoV-2 drugs will be identified from chemical libraries of compounds (collections of chemical compounds) approved...
Use of MAP kinases inhibitors (drugs already approved by the FDA and EMA), for use as treatment in COVID19 patients, preventing the viral spread and inflammatory response resulting from the infection.In the absence of a vaccine and/or specific treatment, the current...
Rapid identification of antiviral compounds and/or inhibitors that block SARS-CoV-2 infection:Antiviral compounds (i.e., that can be used to treat virus infections) and/or compounds that prevent SARS-CoV2 infection will be identified.Three parallel approaches will be...
Platform for the massive screening of antiviral compounds, by means of two phases, one that is developed in the P2 laboratory with a model of the common cold coronavirus and another that is carried out in the P3 laboratory where the selected compounds are evaluated...
This research group has different in vitro and in vivo models for the study of human coronavirus pathogenesis and is finalizing the development of specific models for SARS-CoV-2. These models will be used for preclinical validation of therapeutic compounds against...
The aim of this line of action is to obtain neutralising antibodies against SARS-CoV-2, using the technology of generating single domain antibodies with a human VH region and a camelid VHH domain (nanobodies) in bacteria, starting from available nanobody libraries,...
To characterize the alterations of the cellular metabolism in order to intervene pharmacologically and prevent or reverse the progression of the SARS-CoV-2 infection. These alterations must be identified in order to identify which of them are essential for the...
To advance in the understanding and treatment of the COVID-19 disease, through a structural study of the SARS-CoV-2 virus. Highly pathogenic human respiratory coronaviruses cause an acute lethal disease characterized by exuberant inflammatory responses and lung...
A set of SARS-CoV-2 specific TIPs that can be used for antiviral treatment.Incomplete or defective viral genomes interfere with the reproduction of the virus.These shortened genomes can form particles called DIPs (Defective Interfering Particles) which can be produced...
Use systems capable of hosting several antiviral drugs and develop innovative therapies to fight SARS-CoV-2.As a specific medicinal product against SARS-CoV-2 has not yet been identified, an economical and effective therapeutic strategy is to re-use existing drugs...
Development of a new generation of drugs (Protacs).This is an already active project to create new Protacs drugs (a type of precision drug, more efficient than classic drugs) for human pathologies, aimed at the therapeutic target IMPDH (therapeutic targets are the...
Repositioning of existing clinical drugs to reverse the metabolic reprogramming of SARS-CoV-2 infected patients.Viral infection reprograms the cellular metabolism of those infected to provide viruses with the energy and resources needed to generate new viral...
To test the antiviral effect against SARS-CoV-2 of a variety of inhibitors to provide a basis for short/medium term treatment for patients with COVID-19.To evaluate the effectiveness against human coronaviruses of derivatives of the foot and mouth disease virus genome...
Development of innovative new therapies through a peptide detection test that can prevent the entry of the SARS-CoV-2 virus into our body, and bring it into clinical practice.Principal Investigator: Bruno Sainz Anding (IIB)ISCIII COV20_00749
Increased understanding of the SARS-CoV-2 virus to immediately identify targets for the use of already approved drugs and, in the medium term, to develop new ones. They will characterize the partial structure and dynamics of three proteins and three peptides of...
Identify compounds in clinical use that are capable of effectively interrupting the spread of SARS-CoV-2 in the body.SARS-CoV-2 depends on microtubules (set of molecules involved in cellular processes) for its release, therefore, microtubules can be an effective...
To clarify the role of vimentin as a co-receptor in the SARS-CoV-2 infection, providing an additional therapeutic target that could be valuable considering the severity of the clinical course of this infection and the need for combined therapies.Drugs or strategies...
To identify new, more effective inhibitors that, together with the structural study of Mpro protease dimerization, represent a new approach to the development of effective therapies against the SARS-CoV-2 virus. The genome of betacoronaviruses such as SARS-CoV and...
Discovery and identification of new antiviral compounds effective against COVID-19 based on preliminary results in the detection of its internal library of compounds, recent structural studies with fragments and inhibitors of the main protease (Mpro) of SARS-CoV-2,...
Implementation and setup of a platform for the identification of new compounds with anti-coronavirus activity. The setting up of new screening models and platforms will allow to greatly expand the capacity of analysis of new anti-coronavirus compounds.Having a...
The main objective of this project is the specific elimination of senescent cells using senolytics (drugs that selectively induce the death of senescent cells). As we age, our body accumulates senescent cells, which produce harmful effects in the body, and which could...